Eventide Asset Management INBX Position
Exited3-Fund ConvergenceEventide Asset Management exited their position in Inhibrx Biosciences, Inc. (INBX) in Q4 2023, after holding the stock for 2 quarters.
The position was first reported in Q3 2023 and has been tracked across 2 quarterly 13F filings.
INBX is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for INBRX-106 - Hexavalent OX40 agonist antibody in 197 days (Oct 30, 2026), making the timing of Eventide's position particularly relevant.
Short interest stands at 17.5% of float with 11.2 days to cover, indicating significant bearish positioning against the stock.
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Full company profile →Short Interest
17.5%
11.2 days to cover
Eventide Asset Management INBX Position History
Frequently Asked Questions
Does Eventide Asset Management own INBX?
No. Eventide Asset Management exited their position in Inhibrx Biosciences, Inc. (INBX) in Q4 2023. They previously held the stock for 2 quarters.
How many hedge funds own INBX?
3 specialist biotech hedge funds currently hold INBX, including RA Capital Management, Perceptive Advisors, Tang Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy INBX?
Eventide Asset Management's position in INBX was first reported in Q3 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's INBX position increasing or decreasing?
Eventide Asset Management completely exited their INBX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
INBXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →